Patterson Companies Inc
The Key Factors in Dentsply Sirona Sales Growth Plan
Dentsply Sirona (XRAY) has delivered lower merger synergies than the company had estimated. It also took an impairment charge during 4Q17.
Key Risks Facing PetMed Express in 2017
PetMed Express (PETS) stock has risen 77% in the last one-year period, reaching a high of $50.06 on July 26, 2017.
New Customer Acquisition Drives Revenue Growth for PetMed Express
In 2017, the PetMed Express (PETS) website attracted ~32.0 million visitors, ~8.0% of whom placed an order for a conversion ratio of ~25.0%.
Analysts’ Recommendations for PetMed Express and Peers in 2017
Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
Does Novartis See Much Potential for Its Surgical Business?
In 2017, Novartis (NVS) has planned to conduct a review of its Alcon segment to evaluate the business’s growth potential.
Henry Schein Acquired RxWorks and Greggs Increased Sales
Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.
How Does Patterson Companies Compare to Its Peers?
The respective PE ratios of Patterson Companies and peers Henry Schein, DENTSPLY International, and VCA are 23.6x, 27.1x, 31.5x, and 25.9x as of November 24.
Analyzing Sirona Dental Systems’ Rise in Revenue in Fiscal 4Q15
After the release of Sirona Dental Systems’ (SIRO) 4Q15 earnings report, SIRO rose by 0.23% to close at $109.22 per share on November 20, 2015.
Alnylam and ISIS Lead Mid-Cap Stocks
Alnylam and ISIS led mid-cap stocks from August 25–31, 2015. Alnylam Pharmaceuticals (ALNY) has a weight of 1.60% in IBB and 1.15% in XBI. The stock gained 10.89% in that period.